Considering the relatively low prevalence of genomic events affecting TNFRSF17 and the relative lack of recurrent genomic drivers selected at progression in patients with suboptimal response and/or primary refractory disease, we hypothesized that resistance to CART might be driven by pre-existing genomic drivers. Here, TNFRSF17 is linked to glycogen storage disease VI.